We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Inhibition of Polarity Protein Gene Triggers Cancer-Like Changes in Cell Shape

By LabMedica International staff writers
Posted on 02 Jul 2009
Researchers have identified a gene linked to the mechanism that determines cell shape and have shown how its lack characterizes certain types of cancer cells.

Investigators from the University of Virginia (Charlottesville, USA) used a novel shRNA lentiviral system to manipulate gene expression in mouse mammary stem/progenitor cells. More...
The shRNA specifically inhibited expression of the protease activated receptor 3 (PAR3) gene. This gene encodes a polarity protein that controls how cells acquire particular shapes, so that they have a top and a bottom.

Results published in the June 15, 2009, issue of the journal Genes & Development revealed that transplantation of Par3-depleted stem/progenitor cells into the mammary fat pad severely disrupted mammary development. The investigators identified a novel function for the atypical protein kinase C (aPKC)-binding domain of Par3 in restricting Par3 and aPKC to the apical region of mammary epithelia in vivo, and found that mammary morphogenesis was dependent on the ability of Par3 to directly bind aPKC.

These results revealed a new function for Par3 in the regulation of progenitor differentiation and epithelial morphogenesis in vivo and demonstrated for the first time an essential requirement for the Par3–aPKC interaction.

"A big problem in biology is that there are many thousands of genes. Testing the function of any one of them in a living organism, such as a mouse, has traditionally been slow and very expensive,” said senior author Dr. Ian Macara, professor of microbiology at the University of Virginia. "The new technology is hundreds of times cheaper and many times faster than traditional approaches. While we used it to study the function of a specific breast-developing gene, our method can be replicated in screening for genes that can suppress tumors or cause cancer.”

Related Links:

University of Virginia




New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
ESR Analyzer
TEST1 2.0
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.